Burcon NutraScience Corp.
- WKN: 157793
- ISIN: CA1208311029
- Land: Kanada
Nachricht vom 11.12.2019 | 17:45
Burcon Closes Non-Brokered Private Placement of Convertible Debentures for $9.5 Million
DGAP-News: Burcon NutraScience Corp.
/ Key word(s): Miscellaneous
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
"We are thrilled to have attracted such significant funding in a challenging market." said Johann F. Tergesen, Burcon's president and chief executive officer, adding, "The funds raised will strengthen Burcon's balance sheet, with a portion earmarked for investment into Merit Functional Foods' plant protein production facility, which Burcon and its joint venture partners are building. We are thankful for the solid support shown by our investors."
Each Convertible Debenture consists of $1,000 principal amount, bears interest at a rate of 8.5% per annum, payable semi-annually in arrears, and is unsecured. The principal amount outstanding under the Convertible Debentures and all accrued and unpaid interest thereon will be payable in cash thirty-six (36) months from the date of issuance of the Convertible Debentures. The Convertible Debentures are convertible at the option of the holder, in whole or in part, into common shares of the Corporation (the "Shares") at a conversion price of $1.05 per Share (the "Conversion Price"). An aggregate of up to 9,047,619 Shares are issuable on conversion of the Convertible Debentures, 1,904,761 of which are issuable to insiders of Burcon who subscribed for Convertible Debentures.
Burcon has the right, at its sole discretion, to force the conversion of the Convertible Debentures if the Shares trade at or above $2.15 per share for a period of 14 consecutive trading days. The Convertible Debentures and the Shares issuable upon conversion of the Convertible Debentures are subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws, which is due to expire on April 11, 2020.
The Company has paid a cash finder's fee in connection with the Offering to certain finders in the aggregate amount of $156,600, which represents 4.5% of the gross proceeds received from investors introduced to the Company by the finders.
The Company intends to use the net proceeds from the Offering as set out in its news release dated November 25, 2019 announcing the initial Offering.
The issuance of Convertible Debentures to insiders under the Offering is considered a related party transaction under Multilateral Instrument 61-101. Burcon is relying on exemptions from the formal valuation and minority shareholder approval requirements provided under sections 5.5(a) and 5.7(a) of Multilateral Instrument 61-101 on the basis that the participation in the Offering by insiders does not exceed 25% of Burcon's market capitalization. The Offering was unanimously approved by the disinterested directors of Burcon.
The securities being offered under the Offering have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.
About Burcon NutraScience Corporation
This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward- looking statements or forward-looking information can be identified by words such as "anticipate," "intend," "plan," "goal," "project," "estimate," "expect," "believe", "future," "likely," "may," "should," "could", "will" and similar references to future periods. All statements other than statements of historical fact included in this release are forward-looking statements, including, without limitation, statements regarding expectations, intentions and plans contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the actual results of business negotiations, marketing activities, adverse general economic, market or business conditions, regulatory changes and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form dated July 2, 2019 filed with the Canadian securities administrators on www.sedar.com. Any forward-looking statement or information only speaks as of the date on which it was made and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and accordingly, investors should not rely on such statements.
Burcon NutraScience Corporation Announces Clos ...
Burcon NutraScience Corp.: Burcon Commences Tr ...
Burcon NutraScience Corp.: Burcon NutraScience ...
Burcon NutraScience Corp.: Burcon, Merit and N ...
Burcon NutraScience Corp.: Merit Functional Fo ...
HELMA Eigenheimbau: Klarer Kauf
Die HELMA Eigenheimbau hat mit dem Zugang weiterer Ferienimmobilienprojekte das potenzielle Umsatzvolumen um 150 Mio. € gesteigert. Ohnehin verfügt die Gesellschaft über einen umfangreichen Grundstücksbestand für das Bauträgergeschäft, womit in den kommenden Geschäftsjahren Umsätze in Höhe von über 1,4 Mrd. € realisiert werden könnten. Damit dürften unsere Schätzungen, in denen wir ein nachhaltiges Überschreiten der Umsatzmarke von 300 Mio. € annehmen, gut unterfüttert sein. Bei einem Kursziel von 65,00 € ist die HELMA-Aktie ein klarer Kauf.
Der AKTIONÄR News
24. Februar 21:55 Lufthansa, TUI, Ryanair: Bedrohung Coronavirus
24. Februar 20:35 Apple-Aktie unter Druck: "Es wird noch schlimmer"
24. Februar 20:18 Wirecard und Deutsche Bank: Die großen Coronavirus-Verlierer?
24. Februar 19:55 Volkswagen und DAX: Hinweis auf Ende der Corona-Krise?
News im Fokus
Linde plc: Linde Declares Dividend Increase for 2020
24. Februar 2020, 16:34
Original-Research: ADVA Optical Networking SE (von First Berlin Equity Research GmbH): Hinzufügen
24. Februar 2020